| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
|---|
| Outline of Final Research Achievements |
Androgen and androgen receptor (AR) is the main axis of prostate cancer growth. AR antagonists in androgen deprivation therapy for prostate cancer often show agonistic action and lead to prostate cancer growth; however, the mechanisms of agonistic changes are unknown. We elucidated the agonistic change of the antagonists of androgen receptor of the prostate cancer using changes of the cofactors. We detected the enhanced expression of NKX3-1 during the agonistic change of antagonist of flutamide for prostate cancer cells using real-time PCR and Western Blot analyses. We did not detect the change of the expression of NKX3-1 and agonistic action while adding the antagonist, bicalutamide, to prostate cancer cells.
The agonistic change of the antagonists of androgen receptor of the prostate cancer in the results of this research can develop into the new treatment strategy that targets the mechanism.
|
